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Abstract: Obstructive sleep apnoea (OSA) is a global health problem of increasing prevalence. Effective 
treatments are available with continuous positive airway pressure (CPAP) therapy and mandibular 
advancement devices (MAD). However, there is limited long-term adherence to therapy, as CPAP and MAD 
require permanent usage to avoid recurrence of the symptoms and adverse ill health. Alternative treatments 
would aid in the treatment cascade to manage OSA effectively whenever standard therapy has been trialled 
and failed. Hypoglossal nerve stimulation (HNS), an invasive approach to stimulate the pharyngeal dilator 
muscles of the upper airway during sleep, has been approved for the treatment of OSA by several healthcare 
systems in recent years. In parallel to the development of HNS, a non-invasive approach has been developed 
to deliver electrical stimulation. Transcutaneous electrical stimulation in obstructive sleep apnoea (TESLA) 
uses non-invasive electrical stimulation to increase neuromuscular tone of the upper airway dilator muscles 
of patients with OSA during sleep. Data from previous feasibility studies and randomised controlled 
trials have helped to identify a subgroup of patients who are “responders” to this treatment. However, 
further investigations are required to assess usability, functionality and task accomplishment of this novel 
treatment. Consideration of these factors in the study design of future clinical trials will strengthen research 
methodology and protocols, improve patient related outcome measures and assessments, to optimise this 
emerging therapeutical option. In this review, we will introduce a conceptual framework for the TESLA 
home programme highlighting qualitative aspects and outcomes.
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Introduction
Obstructive sleep apnoea (OSA) is a global health problem 
associated with increased morbidity and mortality (1-4). 
Patients with OSA experience repetitive upper airway 
closure during sleep which results in complete or partial 
cessation of airflow and causes oxygen desaturations; 
the airway closure leads to arousal from sleep, causing 
sleep fragmentation and daytime symptoms (5). OSA 
puts patients and others at risk of injury due to road 
traffic accidents (6,7) caused by drowsiness and results in 
decreased neurocognitive function (8); OSA is associated 
with increased cardiovascular risk (3), hypertension (9,10) 
and endothelial dysfunction (11), potentially contributing 
to myocardial infarction (12), stroke (13) and congestive 
heart failure (14). In addition to hypertension, risk factors 
associated with OSA include the male gender, age, obesity 
and smoking (15-18).
Various factors contribute to upper airway obstruction 
during sleep (19,20), including an abnormal anatomy 
(e.g., a narrow upper airway, enlarged tonsils, adenoids, 
retrognathia, obesity) and decreased neuromuscular tone 
(5,21-24). Different anatomical levels of upper airway 
obstruction, the severity of OSA, posture and sleep state can 
all influence the efficacy of treatment (24-28). The best way 
to assess OSA severity is overnight polysomnography (“sleep 
study”), although symptom questionnaires and risk scores 
are used in the clinical setting and in population-based 
studies, and are essential to identify patients and define the 
syndrome (21,29). 
Currently available treatments for OSA include 
continuous positive airway pressure (CPAP), mandibular 
advancement devices (MAD) and dental devices (30-33), 
lifestyle advice, weight loss and positional therapy (34), 
maxillo-mandibular surgery and ENT interventions (e.g., 
uvulopalatopharyngoplasty) (35) and, less frequently, non-
invasive ventilation (5). CPAP remains the Gold-standard 
treatment (36,37), however, there is limited long-term 
adherence to CPAP and only about half of the patients will 
use it for the recommended four hours a night during at 
least five days a week after one year (5,38,39). The clear 
association between obesity and sleep apnoea (5,23,40-43) 
underlines the importance of developing effective 
treatments for weight loss to complement CPAP therapy. 
Hypoglossal nerve stimulation (HNS) has been recently 
developed as a novel treatment for OSA (44,45). It requires 
the implantation of a stimulator cuff that is in contact 
with the hypoglossal nerve; it works by increasing the 
neuromuscular tone of the upper airway dilator muscles 
and thereby maintaining a patent upper airway during 
sleep (46-48). However, delivery of electrical stimulation is 
not exclusively an invasive option. A similar effect on the 
neuromuscular tone of the upper airway dilator muscles 
(49,50) can be achieved non-invasively by the use of 
transcutaneous electrical stimulation (46,47). Patient-and-
public-involvement (PPI) surveys have shown that patients 
with OSA, even those who are adherent to CPAP therapy, 
are interested in the development and the testing of novel 
and particularly non-invasive treatments (51). Participation 
in and recruitment to future clinical trials will benefit from 
this involvement.
In 2014, HNS was approved by the United States 
Food and Drug Administration (FDA) (52), and there 
are now post-market research registries and studies (e.g., 
Germany). In the UK, the National Institute for Health and 
Care Excellence (NICE) has published its interventional 
procedure guidance on HNS (IPG598) (53).  The 
transcutaneous approach (TESLA) is currently undergoing a 
domiciliary feasibility study (TESLA home; NCT03160456, 
for the protocol see online: http://fp.amegroups.cn/cms/
jtd.2019.05.04-1.pdf), involving three-months treatment 
and assessment.  The TESLA home methodology 
delivers electrical current via transcutaneous patches in 
the submental area, targeting the genioglossus muscle 
to maintain airway patency. This randomised controlled 
trial recruits patients with OSA (apnoea-hypopnoea index 
5–35/hour) who have failed to use CPAP effectively (usage 
<4 hours/night). Slim, overweight and mildly obese subjects 
(body-mass index, BMI<32 kg/m2) with an antero-posterior 
wall collapse and a slim neckline are known to represent 
the phenotype of “responders” to this therapy. In particular 
women with OSA have been identified to benefit from 
this method (50). Similar to the selection criteria utilised 
for HNS, morbidly obese subjects with more severe OSA, 
multi-level or concentric upper airway collapse do not seem 
to sufficiently benefit and are excluded from upper airway 
stimulation trials. In addition to objectively measuring the 
effectiveness of electrical stimulation on preventing upper 
airway collapse, qualitative assessments are important to 
test the feasibility of such a novel treatment. Patients’ 
feedback will help to determine the feasibility of domiciliary 
transcutaneous electrical stimulation, design future clinical 
trials and inform further modification of the technology 
and the device (54). In this review, we will introduce a 
conceptual framework for the TESLA home programme to 
highlight qualitative aspects and outcomes.
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Conceptual framework
A framework was developed based on the conceptual idea to 
capture relevant aspects of the research undertaken in the 
TESLA programme, analyse and address health-regulatory 
body requirements (Medicines & Healthcare Products 
Regulatory Agency, MHRA) and produce qualitative data 
from clinical trials that are not directly linked to primary or 
secondary outcomes of the clinical trial (54). The published 
literature of electrical stimulation for sleep apnoea was 
screened and databases were searched (PubMed, Web 
of Science and Google Scholar) using specific criteria 
(“electrical stimulation”, “transcutaneous electrical 
stimulation”, “hypoglossal nerve stimulation”, “Obstructive 
Sleep Apnoea”, “treatment”, “usability”, “medical devices”, 
“MHRA”); the found results were assessed by two 
independent reviewers (R Tas, M Beach) and included for 
discussion with two other reviewers (M Nido, J Steier) to 
generate and refine a model of a conceptual framework 
for the TESLA programme. The described conceptual 
framework was created with the intention to better assess 
the interaction between the three domains “medical device” 
(TESLA), “user” (patient) and “task” (OSA treatment) (54) 
which are defined as (I) “usability”, (II) “functionality” and 
(III) “task accomplishment” (Figure 1).
“Usability”
The “usability” describes the degree to which the patient 
can make use of a medical device, to achieve quantifiable 
objectives efficiently, effectively and satisfactorily (55) 
(Figure 1). The user experience is complex and can, in part, 
be explained by a model that incorporates seven aspects of 
a treatment from the perspective of the user: whether it is 
usable, valuable, useful, desirable, accessible, credible and 
findable (56). “Usability” testing is considered a cornerstone 
in user-centred design, as it provides information about the 
machine-user interaction (57).
The perceived “usability” of a treatment can affect 
adherence, which is the limiting factor for other sleep 
apnoea treatments like CPAP therapy and MAD. It is 
essential to understand this feature to better treat non-
adherent patients. Long-term adherence depends on 
how individuals judge their personal need for a treatment 
relative to their concerns about its potential adverse effects. 
Adherence is a primary determinant of the effectiveness 
of treatment, good long-term adherence improves the 
effectiveness of therapeutic interventions (58). 
To asses usability quantitative and qualitative approaches 
and methods can be used (59). Questionnaires (quantitative 
method) can rate the “ease of use”, “instructions for use”, 
and the “clarity of the design”, as well as ergonomics on 
given rating scales. With qualitative methods, such as 
(semi-)structured interviews, additional information can 
be gathered assessing patients’ “adherence to intended 
use”, or obvious design errors. The collected quantitative 
and qualitative data can then be used to address issues of 
“usability” and improve the machine-user interaction. 
Patients’ diaries to record practicability and potential 
adverse events can further measure “usability” of 
transcutaneous electrical stimulation for OSA (60).
Psychological and personal aspects of a patient are 
essential characteristic when discussing “usability”, as they 
will affect any interaction with medical devices (61-63). 
Additionally, the attitude to treatment can be positive, 
negative or neutral based on previous experiences and 
expectations, as it is set out in motivational theories, such as 
the Valence-Instrumentality-Expectancy (V-I-E) model (64). 
Motivation to use a device can therefore be explained as a 
multiplied connection of expectancy of a certain outcome 
(“the device will help to improve my health”) and the value 
of the result (“better health is of high relevance to the 
patient”).
The following assessment can assist to address usability 
of the method:
	Patient comfort and device acceptance: Semiquantitative 
visual analogue scales can be used to assess the comfort 
of a new treatment (‘very much/very good’/“0” points, 
to ‘not at all/terrible’/“10”points) (54). In the context 
of TESLA, this can be used to identify adverse 
effects that can arise from the treatment, such as ‘skin 
discomfort’.
Figure 1 Schematic proposal of a conceptual framework TESLA. 
A: refers to “usability” to reflect the interaction between patient 
and device; B: refers to “functionality” to describe the link between 
device and task; C: refers to “task accomplishment” to assess the 
link between patient and task.
Task accomplishment
Patient Task
Device
FunctionalityU
sa
bil
ity
A B
C
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	Qualitative and descriptive parameters and feedback: 
Patient feedback about usage, acceptance, problems 
and perceived benefits, may assess acceptability of a 
novel treatment. Difficulties with the device, such as 
reliability, faults, ease of use, can be useful to modify 
the feasibility of the machine and, in the case of the 
TESLA programme, also the skin interface (hydrogel/
patches).
In the context  of  TESLA-home the descr ibed 
features play an important role (Figure 2; online: http://
fp.amegroups.cn/cms/jtd.2019.05.04-1.pdf) and patient-
and-public-involvement (PPI) (51) was undertaken at an 
early stage to understand the user, the task and physiological 
requirements, encourage early and active involvement, 
incorporate user-centred evaluations, address the entire 
user experience, encourage a multi-disciplinary design, and 
continuously engage with the users during the process (ISO 
9241-210) (65).
“Functionality” 
The “functionality” tests the interaction between the 
‘device’ and the ‘task’, it could also be described as efficacy 
in achieving a sufficient contraction of the dilator muscles 
of the upper airway to avoid upper airway obstruction 
(Figure 1). It assesses whether the muscles are sufficiently 
stimulated, and is further characterised by the suitability 
of the method, accuracy, interoperability, security, and 
functionality compliance; these features aim to satisfy 
the stated or implied needs (66). To maximise the effect 
and increase the neuromuscular tone of the genioglossus, 
improve upper airway patency and, thereby, treat OSA, 
some parameters including several basic properties of the 
medical device such as current, pulse width, stimulation 
frequency, wave form and pad shapes (size, location, uni- 
vs. bilateral stimulation, material), and stimulation timing 
(triggered, intermittent, continuous) could be varied to 
further refine the treatment. These variables impact on the 
generated force, the fatiguability on the neuromuscular 
junction, the skin sensation and the tolerability of the 
method.
Relevant MHRA guidelines (67)
The MHRA have issued relevant guidance on device 
resilience. To be resilient, the medical device’s functioning 
and performance should not be affected adversely through 
normal conditions of use over time. Furthermore, the 
device measurements and outputs must be accurate and 
remain so for the duration of the devices use with any 
accuracy limits clearly specified. Any measurements made 
should be expressed in the appropriate units as described in 
the Council Directive 80/181/EEC, and functions involving 
measuring and monitoring should be developed according 
to ergonomic principles. Devices involving electronic 
systems must be designed to function according to their 
intended use with ensured reliability and repeatability of 
performance. 
Specific to the TESLA methodology, it is important 
to measure a number of quantitative variables that help 
the understanding of the effect on the targeted muscles, 
describe physiological changes on the airway structure and 
the skin sensation of the electrical activity:
 Imaging to observe muscle contraction and improvement 
in upper airway patency: 
 Upper airway magnetic resonance imaging (MRI) 
or computer tomography (CT) can be used to 
accurately visualize and calculate the diameter 
(mm2) of the upper airway awake and during sleep, 
as well as with the stimulation turned ‘on’ or ‘off’. 
 Ultrasound is ubiquitous available in hospitals and 
can be used to identify and localise upper airway 
obstruction (68). The genioglossus can be visualised 
in different planes (49,68) and the contraction of 
this muscle during stimulation can be tested at the 
bedside. Ultrasound measurements (frequency 5 to 
13 MHz, Figure 3) can track significant contraction 
in the genioglossus during stimulation.
 Endoscopy of the upper airway is an option to 
evaluate the severity of upper airway obstruction 
(69,70) and offers the chance to assess upper airway 
patency during stimulation (Figure 4).
Figure 2 Picture of one of the prototypes of the TESLA programme 
attached to the submental area. 
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 Electromyography of the submental muscles can 
record targeted muscle activity (49,71-73).
For the TESLA home trial, physiological measurements 
focus on upper airway morphology and muscle contractions 
during electrical stimulation using ultrasound, upper 
airway endoscopy in the awake participants and functional 
assessments (see online: http://fp.amegroups.cn/cms/
jtd.2019.05.04-1.pdf); these measurements are available at 
the bedside in most clinical settings.
“Task accomplishment” 
The interaction between the user and the task/goal can 
be further described to determine “task accomplishment”, 
which can be assessed subjectively as well as objectively. 
Patients’ preconception of what they believe resembles a 
successful treatment compared with the treating teams’ 
point of view may not be entirely compatible, as they can 
prioritise different criteria [e.g., sleepiness vs. apnoea-
hypopnoea index (AHI)].
Objectively, treatment data can be measured using tools 
that provide quantitative results related to the assessment 
of sleep, restoration of sleep architecture and improved 
symptom control, quality of life and mastery. The main 
outcome parameter for clinical trials in OSA is typically the 
AHI that is used to define severity of the disease. However, 
the following parameters can be used to further address 
objective assessments:
 Nocturnal polysomnography results are the Gold 
standard to assess OSA severity and treatment 
efficacy (74). Certain indices derived from the 
polysomnography are of importance when describing 
upper airway patency and functional assessment 
during sleep:
 Apnoea-hypopnoea index (AHI): the AHI is the 
number of apnoea’s (airflow absence for ≥10 seconds) 
and hypopnoeas (reduction in respiratory effort 
by ≥30%, associated with oxygen desaturation of 
≥3% and/or arousal) per hour of recorded sleep. 
Excessive daytime sleepiness and an AHI greater 
than 5 are key features of OSA. The AHI is a 
standardised method that evaluates both severity 
and treatment outcome for OSA (mild OSA: AHI 
5–14/hour, moderate OSA: AHI 15–30/hour, and 
severe OSA: AHI >30/hour) (75). The AHI does not 
assess the time spent in respiratory events or allow 
the differentiation of hypopnoeas or apnoeas (76). 
An incomplete reopening of the upper airway using 
an insufficient treatment may convert apnoeas into 
hypopnoeas, which would not be reflected accurately 
in the AHI. However, the AHI is a widely accepted 
tool for assessing OSA (52). 
 Oxygen Desaturation Index (ODI): the ODI can be 
recorded according to the desaturation threshold, 
most commonly the 3% or the 4% ODI are reported. 
The ODI is used to assess OSA in clinical settings and 
when tracking treatment of OSA (77-81). 
 Sleep Architecture: this term refers to the cyclical 
pattern of sleep cycles and the preserved features of 
a hypnogram, including non-rapid eye movement 
(N1-3) and rapid eye movement (REM) sleep. OSA 
causes disruption of the natural sleep architecture, 
with frequent arousals leading to numerous sleep 
stage shifts and abnormal cycling of sleep (82). 
On CPAP therapy, patients with OSA have an 
improved sleep quality (83). Similarly, the recording 
of the hypnogram can supplement the assessment 
of treatment and “task accomplishment”.
 Arousal Index (AI): the AI is defined as the number 
of awakenings per hour during a recorded sleep study 
period, it is used in parallel to the hypnogram to 
Figure 3 Ultrasound images of the genioglossus muscle, (A) it 
shows the relaxed muscle (without stimulation) in a coronal view, 
(B) it shows the muscle during electrical stimulation and the 
resulting change in the diameter caused by contraction. As the 
muscle contracts, it shortens, pulling the pharyngeal wall towards 
the anterior direction. An increase in the radius by +10% results 
in an approximate increase in the cross-sectional area (CSA) of the 
muscle of +21%, assuming a round model (CSA= π × r2).
Stimulation on 
(110%)
Stimulation off 
(100%)D1
D1 D2
∆
D2
Coronal view of the submental area, stimulated  
(EMS, continuous, 30 Hz, 250 μs, 11 mA)
TESLA home/ultrasound genioglossus (001)
Coronal view of the submental area, relaxed
A
B
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Figure 4 Endoscopic images of the upper airway. The left panels show the upper airway with the vocal cords and the epiglottis while 
electrical stimulation is turned “off”, the right panel shows the same area when stimulation is turned “on”. The anterior-posterior diameter 
increases with stimulation, the tonsilla lingualis becomes visible just underneath the epiglottis when electrical stimulation is turned on (right 
lower panel).
off on
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understand sleep fragmentation and architecture (84).
 Snoring: snoring is a symptom associated with OSA 
that predominantly affects partners and others. 
However, the percentage of the night that patients 
snore may not reflect the severity of OSA (85), 
although there is a positive correlation between 
louder snoring and severe OSA (86). 
In addition, subjective assessments of “task accomplishment” 
are important, as patients need to be offered the opportunity 
to report on usage, sensation, expectation and efficacy of 
the treatment. The following tools may provide guidance 
for these assessments:
 Epworth Sleepiness Scale (ESS): this is a commonly 
used questionnaire including eight questions about 
patient’s perception of sleepiness, scoring form “0” 
(not at all) to “3” (highly likely to doze). The minimal 
total score is “0” and the maximum “24” points (87). 
A score higher than 8 points has a 76% specificity 
for OSA (88) and treatments for OSA are considered 
effective if the ESS score improves. Accuracy can 
be improved through the use of a patient-partner 
consensus score (89,90); pictorial (91) and online 
ESS (92) are used for screening. However, the 
ESS remains a subjective report and is subject to 
relevant sources of bias and inaccuracy (93). Despite 
its limitations, the minimal clinically important 
difference (MCID) for the ESS has been described as 
an improvement of more than two points (94).
	Berlin Questionnaire (BQ): this questionnaire is 
typically used to screen for OSA. The BQ includes 
questions about snoring, daytime somnolence, body 
mass index (BMI), and hypertension (95). It is a brief 
and validated screening tool that identifies people in 
the community who are at risk of OSA (96). It has a 
high sensitivity but low specificity (97,98).
	Stanford Sleepiness Scale (SSS): the SSS is a self-
reported questionnaire to assess how awake the 
patient feels throughout the day (99). It can be used to 
compare sleepiness in hourly intervals of the day, for 
example prior to new treatment and to assess success 
thereafter. The SSS can be a useful measure to observe 
individual progress and to compare results with other 
studies (99).
	Hospital Anxiety and Depression Scale (HADS): 
the HADS is a tool used for assessing anxiety 
and depression (100,101). It is widely used in 
clinical practice and research. It contains fourteen 
straightforward questions (102). The link between 
depression/anxiety and chronic conditions like OSA 
is well reported (103). Hence, this tool is important in 
the assessment of how OSA affects the mental health 
of an individual. In addition, mental health disorders 
often co-exist with OSA. These conditions can include 
depression, anxiety, schizophrenia, bipolar disorder, 
post-traumatic stress disorder (PTSD) and substance 
use disorders (104). Used as a screening tool, the 
HADS can be added prior to commencing on new 
treatments, and repeatedly measured to follow up on 
the treatment effect (67).
	Functional Outcomes of Sleep Questionnaire (FOSQ): 
this is a validated questionnaire to assess the impact of 
sleepiness on a patient’s ability to perform activities of 
daily living (ADLs) (105). The questionnaire contains 
30 questions, covering 5 subscales (General Productivity, 
Social Outcome, Activity Level, Vigilance, Intimate 
Relationships and Sexual Activity) (106).
	European Quality of Life five dimensions scale 
(EQ-5D): the EQ-5D is used for the standardised 
measurement of health outcomes (107,108) and 
is available in 130 languages (109); the results can 
be used for reference-case analyses and for health-
economics (110). 
	Other Questionnaires: according to a systematic 
review of outcome measures for OSA, the most 
suitable additional assessments include the Maugeri 
OSA syndrome (MOSAS) questionnaire (quality of 
life), the sleep apnoea quality of life index (SAQLI), 
the OSA patient-orientated severity index (OSAPOSI) 
and the Quebec sleep questionnaire (QSQ) (100,111).
The discussion about suitable outcome parameters in 
OSA remains contentious, partially due to the conflict of 
subjective vs. objective disease burden (subjective symptoms 
vs. objective disease severity). However, for any clinical 
trial it is important to capture enough data to describe the 
‘syndrome’ (symptoms and sleep apnoea pathophysiology) 
and, thus, the TESLA home trial includes all of the above 
objective markers, including full polysomnography, and 
many of the symptom questionnaires plus some semi-
quantitative interviews during the follow up period (see 
online: http://fp.amegroups.cn/cms/jtd.2019.05.04-1.pdf).
Conclusions
In order to assess a novel treatment method, as used in the 
TESLA home trial, it is important to understand additional 
components other than the primary outcome parameters of 
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change in disease severity in response to treatment; these 
features define treatment uptake by addressing “usability”, 
“functionality” and “task accomplishment”. The conceptual 
framework for future studies using TESLA methodology 
acknowledges these key elements to address relevant 
guidelines, including those required by the NICE and the 
MHRA. 
The TESLA home programme incorporates the following 
points:
	Development of a human factors engineering (HFE) 
programme within the existing product development 
process that satisfies regulations and standards.
	Design of user interfaces that not only enable safe 
and effective user interactions, but are also perceived 
as usable and appealing by early and continuous 
involvement of the user (PPI).
	Suitable labels and information for users that enable 
and enhance the user’s ability to engage with the 
product effectively and safely (112) and disseminate 
information from clinical trials and device performance.
The proposed patient related outcome measures 
(PROMS) have been designed for future studies and could 
be used to test the efficacy of the treatment; accurate 
recording of PROMS will provide invaluable information 
from clinical trials to refine the method, optimise future 
treatment performance and design study protocols. 
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